Investors'' Presentation on unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 01 Aug 2026, 06:52 PM IST · BSE ID: 3753ddf6-fd88-4004-b098-58d7604eadda
View Original BSE Filing (PDF)
💡
In Simple Terms
Concord Biotech shared its latest quarterly financial update, showing significant increases in sales and profits, particularly from exports.
🤖 AI Summary
- Concord Biotech Ltd reported Q1 FY27 consolidated revenue of Rs. 257.5 Crs, marking a 26% year-on-year growth.
- Consolidated EBITDA increased by 34% year-on-year to Rs. 82.4 Crs, with PAT rising 31% to Rs. 57.7 Crs.
- Exports revenue grew by 46% for Q1 FY27, contributing Rs. 135.8 Crs to total revenue.
- USFDA approvals were received for Mycophenolate Mofetil and Tofacitinib Tablets ANDAs.
- Commercial operations and sales commenced at Stellon Biotech, along with successful regulatory inspections by ANVISA, PPB Kenya, and NDA Uganda.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Q1 FY27 Consolidated Revenue
Rs. 257.5 Crs
+26%
Q1 FY27 Consolidated EBITDA
Rs. 82.4 Crs
+34%
Q1 FY27 Consolidated PAT
Rs. 57.7 Crs
+31%
Q1 FY27 Exports Revenue
Rs. 135.8 Crs
+46%
Q1 FY27 API Revenue
Rs. 218.9 Crs
+42%
Q1 FY27 Formulation Revenue
Rs. 38.6 Crs
-23%
🏢 How This Affects the Company
The company reported broad-based growth across all product categories and geographies, driven by increased wallet share with existing customers and new customer additions. USFDA approvals for new ANDAs and product commercialization at Stellon Biotech expand the product portfolio and market reach.
Consolidated revenue increased by 26% year-on-year, EBITDA by 34%, and PAT by 31%, indicating improved profitability. Gross Profit Margin rose 100 bps to 78.9%, EBITDA Margin by 190 bps to 32.0%, and PAT Margin by 80 bps to 22.4%.
The commencement of commercial operations at Stellon Biotech and advanced customer engagement for injectables signal capacity utilization and diversification. Successful global regulatory inspections strengthen compliance and readiness for international market expansion.
Not applicable — the filing highlights business and financial performance without introducing new risks or mitigating existing ones.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the company's financial performance influences its intrinsic value. The reported growth in revenue and profits indicates the company's operational execution.
🔍
Management Signal
Management's commentary signals a focus on broad-based growth, expanding customer relationships, product portfolio diversification, and strengthening global regulatory credentials.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results – observe API and Formulation revenue trends and overall growth.
Updates on new product launches from the robust product pipeline, targeting 2-3 annually.
Further developments regarding customer engagement for the Injectable Ramp Up segment.
LOW RISK
The filing reports strong financial performance and operational achievements, indicating low immediate risks.
💡 Investor Takeaway
Concord Biotech reported Q1 FY27 consolidated revenue of Rs. 257.5 Crs, up 26% year-on-year, with PAT increasing 31% to Rs. 57.7 Crs. Exports grew 46%, and the company secured USFDA approvals for two ANDAs, confirming operational and financial expansion.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated revenue grew 26% year-on-year to Rs. 257.5 Crs, supported by a 46% increase in exports revenue for Q1 FY27.
- Profitability improved, with EBITDA up 34% to Rs. 82.4 Crs and PAT up 31% to Rs. 57.7 Crs for Q1 FY27.
⚠️ Concerns
- Formulation Revenue decreased by 23% year-on-year, from Rs. 50.2 Crs in Q1 FY26 to Rs. 38.6 Crs in Q1 FY27.
- Domestic revenue growth was lower at 12% compared to export revenue growth of 46% for Q1 FY27.
📅 Company Track Record
No previous filings or specific historical financial data were provided for Concord Biotech Ltd in the context, therefore limited public track record information is available.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Concord Biotech Ltd's consolidated revenue for Q1 FY27?
Concord Biotech Ltd reported a consolidated revenue of Rs. 257.5 Crs for the first quarter ended June 30, 2026, which is a 26% year-on-year increase.
How much did Concord Biotech Ltd's PAT increase in Q1 FY27?
Concord Biotech Ltd's consolidated PAT for Q1 FY27 increased by 31% year-on-year to Rs. 57.7 Crs, compared to Rs. 44.1 Crs in Q1 FY26.
What was the growth in Concord Biotech Ltd's exports revenue for Q1 FY27?
Concord Biotech Ltd's exports revenue for Q1 FY27 grew by 46% year-on-year, reaching Rs. 135.8 Crs.
Did Concord Biotech Ltd receive any USFDA approvals in Q1 FY27?
Yes, Concord Biotech Ltd received approval from USFDA for its ANDA for Mycophenolate Mofetil and Tofacitinib Tablets during Q1 FY27.
What was Concord Biotech Ltd's Formulation Revenue in Q1 FY27?
Concord Biotech Ltd's Formulation Revenue for Q1 FY27 was Rs. 38.6 Crs, which represents a 23% decrease compared to Rs. 50.2 Crs in Q1 FY26.
Questions based on this BSE filing only. For information purposes.